| |
| In today's Daily Pitch, you'll find: | | | | | |
| |
| |
| Real estate's rocky road through 2023 | | Closed-end private real estate funds raised only $98.8 billion in 2023. When the data is finalized, this may still be the lowest fundraising figure since 2012, as lenders pulled back from issuing debt for new projects and high interest rates dampened dealmaking.
Opportunistic and distressed strategies stacked up the most commitments as asset managers and lenders offloaded office portfolios at steep discounts.
Our latest Global Real Estate Report, sponsored by Baker Tilly, breaks down which strategies are still fundraising successfully in the challenging environment, touching on China's struggling market, public vs. private performance and more. | | | | | | | | | Ranking the most active lenders in PE | | The full-year numbers are in: Six lenders took part in at least 150 deals each for US PE-backed companies during 2023, with the most active two tallying upward of 280 apiece.
Which firms led the way? See our 2023 Annual PE Lending League Tables, sponsored by TPG Twin Brook Capital Partners. The interactive tables can be sorted by deal type, geography, sector and more. | | | | | | | |
| |
| A message from Plante Moran | | |
| Drive value creation: Better due diligence with data analytics | | Is your private equity firm investing in data analytics? With deal flow at an all-time high, faster, more informed decision-making is critical. Even a modest utilization of data management and business intelligence tools can save countless hours of information requests and data prep.
Data analytics can significantly streamline the due diligence process, providing: - Faster trend recognition.
- Deeper understanding of KPIs.
- Reduced seller fatigue.
- Increased post-merger value creation.
And more. In this article, Plante Moran explore four use cases for data analytics to help you understand why it's time to invest and how it might help you.
Read the article | | | | | | | |
| |
| Meet the nuclear fusion startups with the deepest pockets | |  | | (Joey Schaffer/PitchBook News) | | | Spurred on by technological breakthroughs and expanded federal funding, VCs are paying more attention to fusion technology as a promising solution to the demands of the global energy transition.
Take a look at our list of the top VC-backed players in the fusion energy space. | | | | | | | | | Tailwinds boost Middle East PE | |  | | Dubai (Mint Images/Getty Images) | | | Buoyed by governmental initiatives to diversify Middle Eastern economies away from oil and gas revenues and a growing on-the-ground presence of international GPs, PE activity in the Middle East and Northern Africa region appears to be developing on strong ground.
In contrast to the US and Europe, the area's total PE deal value grew significantly last year. | | | | | | | | | Biopharma investors focus on quality over quantity | | Despite a 19% quarter-over-quarter decline in deal value in Q4, investor enthusiasm for the biopharma industry is holding strong, particularly for companies integrating AI into drug discovery and those developing weight loss drugs.
Meanwhile, a steady flow of exits returned $18.3 billion to VCs in 2023, the result of an increasingly selective investment approach driven by strong clinical data and recalibrating technology platform investment interest, writes senior analyst Kazi Helal.
Our recent Emerging Tech Research unpacks recent VC trends across the biopharma industry, spotlights key players and highlights emerging opportunities in molecular glue degraders, epigenetic editing and macrocyclic peptides. | | | | | | | |
| |
| |
| | Since yesterday, the PitchBook Platform added: | | 575 Deals | 2364 People | 704 Companies | 35 Funds | | | | | | |
| |
| The Daily Benchmark: 2015 Vintage North American Real Assets Funds | | | | | | |
| |
| A message from M&A Science | | |
Demystify AI's role in M&A | | The buzz around AI makes it easy to feel confused and overwhelmed when determining if and when to adopt it in your M&A practice.
That's why M&A Science has created a bi-weekly webinar series designed to empower M&A professionals with the knowledge and tools to leverage AI to transform their deal-making processes.
Join M&A Science Founder & Chief Scientist, Kison Patel as he focuses on: - Demystifying AI's role in M&A to provide practical insights and applications for M&A teams.
- Highlighting cutting-edge AI tools and methodologies that can streamline and enhance the deal lifecycle.
Register now for M&A Science's next session on March 29th at 11am EST here. | | | | | | | |
| |
| |
AI security startup BigID, which is based in New York, raised a $60 million growth round led by Riverwood Capital.
San Francisco's Figure Markets, the operator of a crypto marketplace, raised a $60 million Series A led by Jump Crypto, Faction and Pantera Capital.
Carlsmed, an AI medtech startup based in California, raised a $52.5 million Series C co-led by B Capital and US Venture Partners.
Fintech startup FlexPoint raised $5 million in equity led by Haymaker Ventures and $30 million in debt from Tacora Capital.
Mission Zero, a London-based developer of direct air capture technology, secured £21.8 million in a Series A from investors including 2150, World Fund and Breakthrough Energy Ventures.
Zone, a Nigerian blockchain-enabled payment infrastructure startup, raised $8.5 million in a round led by Flourish Ventures and TLcom Capital.
UpHill Health, a Portuguese developer of software used to guide clinical decision-making, secured a €7 million Series A from investors including Explorer Investments, Redstone and Brighteye Ventures. | | | | | |
| |
| PitchBook webinar: Net asset value loans | | Net asset value loans have emerged in recent years as a solution to support portfolio companies in maintaining liquidity through turbulent conditions. In this on-demand webinar, our panel of experts debates the benefits and drawbacks of NAV loans from both a GP and LP perspective—covering potential tensions around alignment, interest rates and more. Key topics include: - What GPs, LPs and lenders think about use cases for NAV loan proceeds.
- What GPs should know when deliberating using a NAV facility.
- Questions LPs should prepare when GPs are contemplating these loans.
- Improving transparency around NAV loans.
Watch the webinar. | | | | | | | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
No comments:
Post a Comment